Novo Nordisk A/S Shareholders Encouraged to Contact Gross Law Firm for Possible Lead Plaintiff Appointment

Strategic Insights -

According to a notice from the Gross Law Firm, shareholders of Novo Nordisk A/S (NYSE: NVO) who purchased shares during the class period of May 7, 2025, to July 28, 2025, are encouraged to contact the firm regarding possible lead plaintiff appointment. The firm alleges that defendants provided false and misleading statements to investors about Novo's growth potential, understating the impact of the personalization exception to the compounded GLP-1 exclusion and overstating the likelihood of patients switching to Novo's branded alternatives. On July 29, 2025, Novo announced a lower sales and profit outlook, attributing the guide down to the "persistent use of compounded GLP-1s, slower-than-expected market expansion and competition." Following this news, the price of Novo's common stock declined dramatically by 21.83% in a single day.

Key Takeaways:

  • The Gross Law Firm is encouraging shareholders of Novo Nordisk A/S (NYSE: NVO) who purchased shares during the class period of May 7, 2025, to July 28, 2025, to contact the firm regarding possible lead plaintiff appointment.
  • The firm alleges that defendants provided false and misleading statements to investors about Novo's growth potential, understating the impact of the personalization exception to the compounded GLP-1 exclusion and overstating the likelihood of patients switching to Novo's branded alternatives.
  • On July 29, 2025, Novo announced a lower sales and profit outlook, attributing the guide down to the "persistent use of compounded GLP-1s, slower-than-expected market expansion and competition."
  • Following this news, the price of Novo's common stock declined dramatically by 21.83% in a single day.
  • The Gross Law Firm is a nationally recognized class action law firm committed to protecting the rights of investors who have suffered as a result of deceit, fraud, and illegal business practices.
  • The firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.
  • The deadline to seek to be a lead plaintiff is September 30, 2025.

Statistics:

  • The class period for purchasing shares of Novo Nordisk A/S (NYSE: NVO) was May 7, 2025, to July 28, 2025.
  • The price of Novo's common stock declined by 21.83% in a single day on July 29, 2025, from a closing market price of $69.00 per share to $53.94 per share.
  • The deadline to seek to be a lead plaintiff is September 30, 2025.

Sources:

  • The Gross Law Firm notice to shareholders of Novo Nordisk A/S (NYSE: NVO)
  • SOURCE The Gross Law Firm